Exemplary news on July 1, 2013 revealed that Apixaban, known as the brand name Eliquis, had achieved its primary goal in studies. Marketed by both Pfizer and Bristol-Myers Squibb, Apixaban is an effective anticoagulant that has undergone strenuous testing, based on data from a recently released study coined AMPLIFY. Results from this comprehensive study were extremely positive, indicating that Apixaban not only matched standard treatments for potentially fatal blood clots, but it was also deemed to be efficacious and safe. In fact, when compared to its competitor anticoagulant warfarin, Apixaban had a better safety profile, showing a 69% risk reduction for major bleeding events. The AMPLIFY study focused on patients in need of treatment for deep vein thrombosis, or DVT, as well as patients suffering from blood clots in their lungs, also called pulmonary embolism, or PE. The staggering number of patients who experience either DVT or PE each year, in the United States and Europe combined, amounts to almost two million people. This is certainly a patient population that is in need of safe and effectual therapy. The lowered bleeding risk and safety record are definitely causing research and development teams to take notice of this new data in support of Apixaban.
Apixaban was initially approved on December 31, 2012 by the FDA to help reduce the risk of blood clots and stroke in patients who have atrial fibrillation that is not caused by a heart valve problem. Comprehensive studies, coined ARISTOTLE and AVERROES, involved 24,000 patients altogether, and demonstrated both the safety and success of Apixaban. As an anticoagulant that is a direct factor Xa inhibitor (Vitamin K antagonist), Apixaban has proven to be worthy contender in the market for cardiovascular medications. Over 2% of strokes for patients in the United States are attributed to atrial fibrillation, or close to 18,000 strokes annually. Apixaban should not be administered to patients with bleeding problems or who are taking other anticoagulants. Apixaban is available in 2.5 milligram and 5 milligram tablets, and adverse side effects are uncommon.
LGM Pharma provides API Apixaban CAS# 503612-47-3, for research and development purposes. Clients can be assured of continuous support throughout the R&D process, as well as quality API products.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.